$1.14/ day, billed weekly
Cancel anytime

(Ads Free, Unlimited access)

NO CREDIT CARD REQUIRED

OnKure Therapeutics, Inc. (OKUR)OKUR

OnKure Therapeutics, Inc.

$16

Delayed price

Profit since last BUY-9.42%

SELL

SELL since 3 days

BUY Advisory
Profitable SELL
Loss-Inducing SELL

Profit
Loss
PASS (Skip invest)*

Time period over

ALL
YEAR
MONTH
WEEK

Time period over

Upturn Advisory Summary

11/20/2024: OKUR (1-star) is a SELL. SELL since 3 days. Profits (-9.42%). Updated daily EoD!

Analysis of Past Performance

Type: Stock	Upturn Star Rating	Today’s Advisory: SELL
Historic Profit: 119.59%	Upturn Advisory Performance 1	Avg. Invested days: 34
Profits based on simulation	Stock Returns Performance 5	Last Close 11/20/2024

Type: Stock	Today’s Advisory: SELL
Historic Profit: 119.59%	Avg. Invested days: 34
Upturn Star Rating	Stock Returns Performance 5
Profits based on simulation Last Close 11/20/2024	Upturn Advisory Performance 1

Key Highlights

Company Size ETF	Market Capitalization 0 USD
Price to earnings Ratio -	1Y Target Price -
Dividends yield (FY) -	Basic EPS (TTM) -
Volume (30-day avg) 65233	Beta -
52 Weeks Range 9.80 - 77.60	Updated Date 11/17/2024

Company Size ETF	Market Capitalization 0 USD	Price to earnings Ratio -	1Y Target Price -
Dividends yield (FY) -	Basic EPS (TTM) -	Volume (30-day avg) 65233	Beta -
52 Weeks Range 9.80 - 77.60	Updated Date 11/17/2024

Earnings Date

Report Date 2024-11-11	When BeforeMarket
Estimate -1.03	Actual -

Report Date 2024-11-11

When BeforeMarket

Estimate -1.03

Actual -

Profitability

Profit Margin -

Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -

Return on Equity (TTM) -

Valuation

Trailing PE -	Forward PE -
Enterprise Value -	Price to Sales(TTM) -
Enterprise Value to Revenue -	Enterprise Value to EBITDA -
Shares Outstanding -	Shares Floating -
Percent Insiders -	Percent Institutions -

Trailing PE -	Forward PE -	Enterprise Value -	Price to Sales(TTM) -
Enterprise Value to Revenue -	Enterprise Value to EBITDA -	Shares Outstanding -	Shares Floating -
Percent Insiders -	Percent Institutions -

Analyst Ratings

Rating 4.67	Target Price -	Buy 1
Strong Buy 2	Hold -	Sell -
Strong Sell -

Rating 4.67	Target Price -	Buy 1	Strong Buy 2
Hold -	Sell -	Strong Sell -

About OnKure Therapeutics, Inc.

Exchange	NASDAQ	Headquaters	Boulder, CO, United States
IPO Launch date	2024-10-07	President, CEO & Director	Dr. Nicholas A. Saccomano Ph.D.
Sector	Healthcare	Website	https://onkuretherapeutics.com
Industry	Biotechnology	Full time employees	-
Headquaters	Boulder, CO, United States
President, CEO & Director	Dr. Nicholas A. Saccomano Ph.D.
Website	https://onkuretherapeutics.com
Website	https://onkuretherapeutics.com
Full time employees	-

OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3 kinase alpha harboring the H1047R mutation for the treatment of solid tumors, including breast cancer. The company is headquartered in Boulder, Colorado.

https://www.upturn.io

Disclosure Privacy Policy Terms of Use Sitemap Contact Us

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.